Dopamine D2 and serotonin 5-HT2A receptors (antagonist); serotonin transporter (reuptake inhibitor)

Class

fixed-dose combination of an atypical antipsychotic and a selective serotonin reuptake inhibitor

Pathway

combined dopaminergic/serotonergic receptor antagonism with serotonin reuptake inhibition

Notes

original target text: Dopamine D2 and serotonin 5-HT2A receptors (olanzapine, antagonist); serotonin transporter SERT (fluoxetine, reuptake inhibitor)

This combination pairs two receptor mechanisms used together to address severe or treatment-resistant depressive states. One component, an atypical antipsychotic, blocks dopamine D2 receptors and serotonin 5-HT2A receptors, actions associated with antipsychotic and mood-stabilizing effects and, at 5-HT2A, some antidepressant-augmenting properties. The other component, a selective serotonin reuptake inhibitor, blocks the serotonin transporter (SERT), the protein responsible for clearing serotonin from the synaptic space after it is released, thereby prolonging serotonin signaling. The rationale for combining these mechanisms is that severe depressive episodes, particularly those accompanied by psychotic features or that have not responded to standard antidepressant monotherapy, often do not resolve with serotonergic modulation alone. Adding dopaminergic and additional serotonergic receptor blockade broadens the range of neurotransmitter systems engaged, which can produce more robust mood and psychotic-symptom control than either mechanism alone. This dual approach is used broadly in psychiatric contexts such as bipolar depression and depression with psychotic features, where mood, thought, and perception disturbances coexist and a single-mechanism drug is often insufficient. The combination reflects a general principle in psychiatric pharmacology: layering complementary receptor mechanisms to address multidimensional symptom profiles.